Osteoporosis treatment and pain relief: A scoping review

Abstract Background and Objective Anti‐osteoporosis (OP) drugs have been suggested to contribute to pain reduction during OP management. This scoping review aimed at mapping the literature on pain relief with anti‐OP drugs in OP treatment. Databases and Data Treatment Medline, Pubmed and Cochrane databases were searched by two reviewers with keywords combinations. Randomized controlled and real‐life English studies, pain as an endpoint, antiosteoporosis drugs were inclusion criteria. Case reports, surveys, comment letters, conference abstracts, animal studies and grey literature were excluded. Predetermined data were extracted by two reviewers and disagreement solved through discussion. Results A total of 130 articles were identified, 31 publications were included, 12 randomized clinical trials and 19 observational studies. Pain reduction was assessed by different tools: Visual Analogue Scale, Verbal Rating Scale, Facial Scale or as a domain of quality of life questionnaires including Short form 8, 36, mini‐OP, Japanese OP, Qualeffo, Roland Morris Disability questionnaires. Collective data show that anti‐OP drugs may display an analgesic effect that may be linked to the local mode of action of drugs on bone and consecutive modulation of pain sensitization. The methodology of the studies showed a heterogeneity of endpoints, comparators, statistical approaches and follow‐up duration. Conclusion Considering the limitations of the literature, there is a need for more rigorous trials and larger real‐life studies taking into account the recommendations published for research in rheumatology and in pain medicine. The identification of responders, patient subtypes, and of analgesic‐effect doses would allow optimization and individualization for pain relief in patients with OP. Significance Statement This scoping review shows that anti‐OP drugs may improve pain and quality of life of patients with OP. The heterogeneity in design, choice of endpoints, methodology, comparators and follow‐up duration of included randomized clinical trials and real‐life studies does not allow so far to identify a predominant antiosteoporosis drug or an optimal dosage for pain relief. These gaps need to be addressed and warrant further research in the future for optimizing pain improvement in the course of OP drug treatment.